Historical Valuation
Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 77.98 is considered Fairly compared with the five-year average of -2.71. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.67 to 5.46 according to relative valuation methord.
Relative Value
Fair Zone
0.67-5.46
Current Price：4.80
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Orchestra Biomed Holdings Inc (OBIO) has a current Price-to-Book (P/B) ratio of 5.56. Compared to its 3-year average P/B ratio of 31.13 , the current P/B ratio is approximately -82.13% higher. Relative to its 5-year average P/B ratio of 19.01, the current P/B ratio is about -70.73% higher. Orchestra Biomed Holdings Inc (OBIO) has a Forward Free Cash Flow (FCF) yield of approximately -24.98%. Compared to its 3-year average FCF yield of -23.94%, the current FCF yield is approximately 4.33% lower. Relative to its 5-year average FCF yield of -23.94% , the current FCF yield is about 4.33% lower.
P/B
Median3y
31.13
Median5y
19.01
FCF Yield
Median3y
-23.94
Median5y
-23.94
Competitors Valuation Multiple
AI Analysis for OBIO
The average P/S ratio for OBIO competitors is 19.37, providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO.O) exhibits a P/S ratio of 77.98, which is 302.53% above the industry average. Given its robust revenue growth of -12.77%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for OBIO
1Y
3Y
5Y
Market capitalization of OBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OBIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is OBIO currently overvalued or undervalued?
Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 77.98 is considered Fairly compared with the five-year average of -2.71. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.67 to 5.46 according to relative valuation methord.
What is Orchestra Biomed Holdings Inc (OBIO) fair value?
OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.67 to 5.46 according to relative valuation methord.
How does OBIO's valuation metrics compare to the industry average?
The average P/S ratio for OBIO's competitors is 19.37, providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO) exhibits a P/S ratio of 77.98, which is 302.53% above the industry average. Given its robust revenue growth of -12.77%, this premium appears unsustainable.
What is the current P/B ratio for Orchestra Biomed Holdings Inc (OBIO) as of Jan 09 2026?
As of Jan 09 2026, Orchestra Biomed Holdings Inc (OBIO) has a P/B ratio of 5.56. This indicates that the market values OBIO at 5.56 times its book value.
What is the current FCF Yield for Orchestra Biomed Holdings Inc (OBIO) as of Jan 09 2026?
As of Jan 09 2026, Orchestra Biomed Holdings Inc (OBIO) has a FCF Yield of -24.98%. This means that for every dollar of Orchestra Biomed Holdings Inc’s market capitalization, the company generates -24.98 cents in free cash flow.
What is the current Forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO) as of Jan 09 2026?
As of Jan 09 2026, Orchestra Biomed Holdings Inc (OBIO) has a Forward P/E ratio of -2.73. This means the market is willing to pay $-2.73 for every dollar of Orchestra Biomed Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Orchestra Biomed Holdings Inc (OBIO) as of Jan 09 2026?
As of Jan 09 2026, Orchestra Biomed Holdings Inc (OBIO) has a Forward P/S ratio of 77.98. This means the market is valuing OBIO at $77.98 for every dollar of expected revenue over the next 12 months.